Conclusion Tumor size does not appear to correlate with malignancy in a clinically significant manner. Malignant paraganglioma may be more aggressive than malignant pheochromocytoma and is frequently offered more adjuvant therapy. PCC and PG should be evaluated separately in future analyses of these diseases.”
“A diagnosis of advanced BI 2536 ovarian cancer is the beginning of a long and arduous journey for a patient. Worldwide, approximately
half of the individuals undergoing therapy for advanced cancer will succumb to the disease, or consequences of treatment. Well-known and widely- used chemotherapeutic agents such as cisplatin, paclitaxel, 5- fluorouracil, and doxorubicin are toxic to both cancer and non- cancerous cells, and have debilitating side effects Therefore, development of new targeted anticancer therapies that
can selectively kill cancer cells while sparing the surrounding healthy tissues is essential to develop more effective therapies. We have developed a new class of synthetic curcumin analogs, diarylidenyl- piperidones (DAPs), which have higher anticancer activity and enhanced bio- absorption than curcumin. The DAP backbone structure exhibits cytotoxic (anticancer) activity, Cytoskeletal Signaling inhibitor whereas the Nhydroxypyrroline (- NOH) moiety found on some variants functions as a cellular- or tissue- specific modulator (antioxidant) of cytotoxicity. The anticancer activity of the DAPs has been evaluated using a number of JQ1 ovarian cancer cell lines, and the safety has been evaluated in a number of non- cancerous cell lines. Both variations of the DAP compounds showed similar levels of cell death in ovarian cancer cells, however the compounds with the NOH modification were less toxic to non- cancerous cells. The selective cytotoxicity of the DAP- NOH compounds suggests that they will be useful as safe and effective anticancer agents. This article reviews some of the key findings of our work with the DAP compounds, and compares this to some of the targeted therapies currently used in ovarian cancer therapy.”
“OBJECTIVE: To
analyse the results after elective open total aortic arch replacement.
METHODS: We analysed 39 patients (median age 63 years, median logistic EuroSCORE 18.4) who underwent elective open total arch replacement between 2005 and 2012.
RESULTS: In-hospital mortality was 5.1% (n = 2) and perioperative neurological injury was 12.8% (n = 5). The indication for surgery was degenerative aneurysmal disease in 59% (n = 23) and late aneurysmal formation following previous surgery of type A aortic dissection in 35.9% (n = 14); 5.1% (n = 2) were due to anastomotical aneurysms after prior ascending repair. Fifty-nine percent (n = 23) of the patients had already undergone previous proximal thoracic aortic surgery. In 30.8% (n = 12) of them, a conventional elephant trunk was added to total arch replacement, in 28.2% (n = 11), root replacement was additionally performed.
No related posts.